Literature DB >> 21512767

Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.

Sandrine Boyault1, Youenn Drouet, Claudine Navarro, Thomas Bachelot, Christine Lasset, Isabelle Treilleux, Eric Tabone, Alain Puisieux, Qing Wang.   

Abstract

Understanding how cancer genes are mutated in individual tumors is an important issue with potential clinical and therapeutic impact. This is especially relevant with recently developed targeted therapies since mutated genes can be targets and/or predictors. However, to date, gene mutation profiling in individual tumors is still underexplored. Breast cancer is composed of various subtypes. We presumed that this heterogeneity reflected the involvement of different molecular mechanisms including gene mutations that affect defined signaling pathways. Unlike the majority of published mutational studies, this study was aimed to draw a mutation profile in individual tumors by screening a panel of cancer genes in the same tumor. Thus, five genes frequently mutated in breast cancers: TP53, PIK3CA, PTEN, CDH1, and AKT1 were screened in each of 120 human primary breast tumors. Mutations in at least one of these genes were found in 62.5% of the tumors, of which the majority carried a single-gene mutation. Interestingly, a substantial proportion of tumors carried mutations either in TP53 or in genes of the PI3K pathway (PIK3CA or PTEN or AKT1). These two distinct mutation patterns were significantly associated to hormone receptor expression but independent of HER2 status.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512767     DOI: 10.1007/s10549-011-1518-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  35 in total

1.  PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.

Authors:  Lucia Veronica Cuorvo; Paolo Verderio; Chiara Maura Ciniselli; Salvatore Girlando; Nicola Decarli; Elena Leonardi; Antonella Ferro; Alessia Caldara; Renza Triolo; Claudio Eccher; Chiara Cantaloni; Francesco Mauri; Michael Seckl; Marco Volante; Fiamma Buttitta; Antonio Marchetti; Quattrone Silvia; Enzo Galligioni; Paolo Dalla Palma; Mattia Barbareschi
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

2.  PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.

Authors:  Sarah Croessmann; Hong Yuen Wong; Daniel J Zabransky; David Chu; D Marc Rosen; Justin Cidado; Rory L Cochran; W Brian Dalton; Bracha Erlanger; Karen Cravero; Berry Button; Kelly Kyker-Snowman; Paula J Hurley; Josh Lauring; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2017-02-11       Impact factor: 4.872

3.  Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.

Authors:  Aggeliki Tserga; Ilenia Chatziandreou; Nicolaos V Michalopoulos; Efstratios Patsouris; Angelica A Saetta
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

4.  Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP.

Authors:  Elena Valentino; Arianna Bellazzo; Giulio Di Minin; Daria Sicari; Mattia Apollonio; Giosuè Scognamiglio; Maurizio Di Bonito; Gerardo Botti; Giannino Del Sal; Licio Collavin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-30       Impact factor: 11.205

Review 5.  Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.

Authors:  L G Estévez; E García; M Hidalgo
Journal:  Clin Transl Oncol       Date:  2015-10-28       Impact factor: 3.405

6.  PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.

Authors:  Mattia Barbareschi; Lucia Veronica Cuorvo; Salvatore Girlando; Emma Bragantini; Claudio Eccher; Elena Leonardi; Antonella Ferro; Alessia Caldara; Renza Triolo; Chiara Cantaloni; Nicola Decarli; Enzo Galligioni; Paolo Dalla Palma
Journal:  Virchows Arch       Date:  2012-06-29       Impact factor: 4.064

Review 7.  AKT in cancer: new molecular insights and advances in drug development.

Authors:  Prabhjot S Mundi; Jasgit Sachdev; Carolyn McCourt; Kevin Kalinsky
Journal:  Br J Clin Pharmacol       Date:  2016-06-27       Impact factor: 4.335

8.  Pathway-based analysis of breast cancer.

Authors:  Dong Song; Miao Cui; Gang Zhao; Zhimin Fan; Katherine Nolan; Ying Yang; Peng Lee; Fei Ye; David Y Zhang
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

Review 9.  Genetically engineered mouse models of PI3K signaling in breast cancer.

Authors:  Sjoerd Klarenbeek; Martine H van Miltenburg; Jos Jonkers
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

Review 10.  Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.

Authors:  Justin Cidado; Ben Ho Park
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-08-04       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.